Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer

Journal of Translational Medicine
David O HoltzGeorge Coukos

Abstract

Because of its low toxicity, low-dose (LD) chemotherapy is ideally suited for combination with antiangiogenic drugs. We investigated the impact of tumor vascular endothelial growth factor A (VEGF-A) expression on the efficacy of LD paclitaxel chemotherapy and its interactions with the tyrosine kinase inhibitor SU5416 in the ID8 and ID8-Vegf models of ovarian cancer. Functional linear models using weighted penalized least squares were utilized to identify interactions between Vegf, LD paclitaxel and antiangiogenic therapy. LD paclitaxel yielded additive effects with antiangiogenic therapy against tumors with low Vegf expression, while it exhibited antagonism to antiangiogenic therapy in tumors with high Vegf expression. This is the first preclinical study that models interactions of LD paclitaxel chemotherapy with antiangiogenic therapy and tumor VEGF expression and offers important lessons for the rational design of clinical trials.

References

Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M M Tomayko, C P Reynolds
Dec 13, 1997·Anti-cancer Drugs·H J Muenchen, S K Aggarwal
Aug 14, 2001·European Journal of Immunology·C A Byrd-LeiferA Ding
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R S KerbelB Kamen
Mar 14, 2002·Biometrics·Wensheng Guo
Mar 21, 2002·The Lancet Oncology·G Gasparini
Apr 12, 2002·Biochemical and Biophysical Research Communications·Lin ZhangGeorge Coukos
Dec 11, 2002·Expert Opinion on Pharmacotherapy·Sakkaraiappan Ramalingam, Chandra P Belani
Dec 31, 2002·Critical Reviews in Oncology/hematology·Paolo MarchettiCorrado Ficorella
May 3, 2003·The Journal of Clinical Investigation·Gabriele BergersDouglas Hanahan
Nov 7, 2003·Current Molecular Medicine·Judah Folkman
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarSomnath Sarkar
May 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G BocciM Del Tacca
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hedy L KindlerEverett E Vokes
Dec 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adrian M JubbHartmut Koeppen
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott D YoungColin J Germond
Jun 6, 2006·Gynecologic Oncology·Lukas A HeflerAlexander Reinthaller
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manish A ShahDavid P Kelsen
May 23, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Den HeijerA Tibben

❮ Previous
Next ❯

Citations

Nov 22, 2011·Cancer Metastasis Reviews·Samar Masoumi MoghaddamMohammad H Pourgholami
Sep 30, 2008·Nature Immunology·Maciej M MarkiewskiJohn D Lambris
Jul 18, 2008·Carcinogenesis·Eleanor I AgerChristopher Christophi
Jan 15, 2010·Journal of Oncology·Francois P Duhoux, Jean-Pascal Machiels
Nov 3, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Setsuko K ChambersDavid S Alberts
Jul 6, 2014·Journal of Pharmaceutical Sciences·Ken-Ichi OgawaraKazutaka Higaki
Jan 3, 2012·Cancer Treatment Reviews·Fharat A RajaJonathan A Ledermann
Nov 14, 2016·Cancer Letters·Amr S Abu Lila, Tatsuhiro Ishida
Apr 27, 2017·Critical Reviews in Clinical Laboratory Sciences·Khalid El BairiSaid Afqir

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Software Mentioned

Image
Pro ® Plus

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.